PMID- 10880849
OWN - NLM
STAT- MEDLINE
DCOM- 20000830
LR  - 20221207
IS  - 0169-5002 (Print)
IS  - 0169-5002 (Linking)
VI  - 29
IP  - 1
DP  - 2000 Jul
TI  - A phase II trial testing gemcitabine as second-line chemotherapy for non small 
      cell lung cancer. The European Lung Cancer Working Party. 
      101473.1044@compuserve.com.
PG  - 67-73
AB  - The purpose of the present trial was to determine the activity of gemcitabine as 
      a second-line chemotherapy for non small cell lung cancer (NSCLC). To be 
      eligible, patients had to have pathologically proven NSCLC that has failed to 
      respond to a first-line chemotherapy with a cisplatin-containing regimen, a 
      Karnofsky performance status greater than 50 and adequate renal, haematological 
      and hepatic functions. After registration, patients were treated by gemcitabine 
      given i.v. at a dose of 1 g/m(2) on days 1, 8, 15 every 4 weeks. Response was 
      assessed after two courses of therapy. Eighty-two patients have been registered, 
      five are ineligible and 65 are assessable for response. Four partial responses 
      were observed (6%). No change was documented in 18 cases (28%). Tolerance was 
      good. A few grade III leucopenia and grade III-IV thrombopenia were observed. We 
      conclude that gemcitabine has a modest activity as second-line chemotherapy for 
      NSCLC. It has the advantage to be well tolerated and may thus be one drug to be 
      proposed to the patients who have disease progression after a first-line 
      chemotherapy and who ask for further treatment.
FAU - Sculier, J P
AU  - Sculier JP
AD  - Service de Medecine, Institut Jules Bordet, 1, rue Heger-Bordet, B-1000, 
      Brussels, Belgium.
FAU - Lafitte, J J
AU  - Lafitte JJ
FAU - Berghmans, T
AU  - Berghmans T
FAU - Thiriaux, J
AU  - Thiriaux J
FAU - Lecomte, J
AU  - Lecomte J
FAU - Efremidis, A
AU  - Efremidis A
FAU - Ninane, V
AU  - Ninane V
FAU - Paesmans, M
AU  - Paesmans M
FAU - Mommen, P
AU  - Mommen P
FAU - Klastersky, J
AU  - Klastersky J
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antimetabolites, Antineoplastic/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Deoxycytidine/*analogs & derivatives/therapeutic use
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Salvage Therapy
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - Gemcitabine
EDAT- 2000/07/06 11:00
MHDA- 2000/09/02 11:01
CRDT- 2000/07/06 11:00
PHST- 2000/07/06 11:00 [pubmed]
PHST- 2000/09/02 11:01 [medline]
PHST- 2000/07/06 11:00 [entrez]
AID - S0169500200000994 [pii]
AID - 10.1016/s0169-5002(00)00099-4 [doi]
PST - ppublish
SO  - Lung Cancer. 2000 Jul;29(1):67-73. doi: 10.1016/s0169-5002(00)00099-4.